Compare compounds
Pick up to 3 compounds to see protocols, mechanisms, study endpoints and safety findings side by side.
Peptijournal · BPC-157 · https://peptijournal.com/compare?c=bpc-157 · Printed
BPC-157
Same goal
01Protocol
- Start
- 0.25 mg
- Range
- 0.25–0.5 mg
- Frequency
- Once or twice daily
- Cycle
- 4–8 weeks
- Vials
- 5 / 10 mg
02Quick calculator
03Mechanism of action
BPC-157 is a 15-amino-acid fragment of a protein found in gastric juice. Preclinical studies associate it with increased growth-hormone-receptor expression, angiogenesis pathways (including VEGF-related signalling) and lower inflammatory cytokines. The exact receptor target is not established.
04Study endpoints
- A 2025 systematic review found 36 studies: 35 preclinical and 1 clinical.
- Animal models showed improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone injuries.
- The only clinical study was a small retrospective series: 7 of 12 patients with chronic knee pain reported relief for more than 6 months.
05Safety & regulatory findings
- Not FDA-approved for any use and listed as prohibited by the World Anti-Doping Agency.
- Reported half-life is under 30 minutes; it is metabolised in the liver and cleared by the kidneys.
- Preclinical safety studies reported no organ toxicity, but the 2025 review found no clinical safety data.
06Citations
2 references · view